| Cardiovascular Risk Management |
1 |
1 |
| Lipids Management |
0 |
0.78 |
| Adherence |
0 |
0.73 |
| Blood |
0 |
0.6 |
| Biomarker |
0 |
0.33 |
| LDL Cholesterol |
0 |
0.25 |
| Revenue and Practice Management |
0 |
0.23 |
| Social Determinants of Health |
0 |
0.21 |
| Aspirin |
0 |
0.13 |
| Europe |
0 |
0.13 |
| Hand |
0 |
0.13 |
| Salary and Compensation |
0 |
0.13 |
| Generics |
0 |
0.11 |
| Biologic Therapy |
0 |
0.09 |
| Cerebrovascular Accident |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Myocardial Infarction (MI) |
0 |
0.09 |
| ACE Inhibitor |
0 |
0.07 |
| Biomedical Technology |
0 |
0.07 |
| California |
0 |
0.07 |
| Health Care Economics |
0 |
0.07 |
| Heart |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| Infarction |
0 |
0.07 |
| Lipoproteins |
0 |
0.07 |
| New York |
0 |
0.07 |
| Statins |
0 |
0.07 |